nach oben

Reactions Weekly

Erschienen in:

01.03.2020 | Case report

Ipilimumab/nivolumab/pembrolizumab

Arthralgia: 11 case reports

Erschienen in: Reactions Weekly | Ausgabe 1/2020

Einloggen, um Zugang zu erhalten

Excerpt

Author Information

An event is serious (based on the ICH definition) when the patient outcome is:

* death
* life-threatening
* hospitalisation
* disability
* congenital anomaly
* other medically important event

…

The age group was not captured as 'adult' even though the title states 'adult', since the mean age of patients receiving nivolumab was provided as 67.7 years in the source article, implying that some patients are elderly. It can not be determined whether the 11 patients described herein are adults or elderly.

Lee J, et al. Evaluation of arthralgias in adult oncology patients receiving immune checkpoint inhibitors. Journal of Oncology Pharmacy Practice 25: 1867-1872, No. 8, 16 Jan 2019. Available from: URL: http://doi.org/10.1177/1078155218822707 CrossRef

Titel: Ipilimumab/nivolumab/pembrolizumab
Arthralgia: 11 case reports
Publikationsdatum: 01.03.2020
Verlag: Springer International Publishing
Erschienen in: Reactions Weekly / Ausgabe 1/2020
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-020-75926-3

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Ipilimumab/nivolumab/pembrolizumab

Arthralgia: 11 case reports

Excerpt

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2020

Benzodiazepine-related ED visits

Furosemide/sodium chloride/spironolactone

Ipilimumab/nivolumab

Bee-venom-allergy-immunotherapy/wasp-venom-allergy-immunotherapy

Mercaptopurine/methotrexate/prednisone

Heparin